SCHEMBL22874530

SCHEMBL22874530

CNc1ccc(OC(C)c2ccccn2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
BRD4 O60885 2/20 0.42
CREBBP Q92793 1/20 0.42
JAK3 P52333 1/20 0.41
KDM4E B2RXH2 4/20 0.38
TSHR P16473 3/20 0.38
SLC6A3 Q01959 2/20 0.38
ABCB11 O95342 1/20 0.38
LMNA P02545 1/20 0.38
ESR1 P03372 1/20 0.38
CYP3A4 P08684 1/20 0.38
ADRA2A P08913 1/20 0.38
CYP2C9 P11712 1/20 0.38
PDE4A P27815 1/20 0.38
ADRA1A P35348 1/20 0.38
OPRK1 P41145 1/20 0.38
STAT6 P42226 1/20 0.38
HIF1A Q16665 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
GABRA1 P14867 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22874531 0.86 TDP1 (0.43) POLBBRD4CREBBPJAK3KDM4E
SCHEMBL10697880 0.83 POLB (0.58) POLBBRD4CREBBPJAK3KDM4E
SCHEMBL22874558 0.81 POLB (0.53) POLBBRD4CREBBPJAK3KDM4E
SCHEMBL3647221 0.77 MAPT (0.57) POLBBRD4CREBBPJAK3KDM4E
SCHEMBL3646089 0.76 KMT2A (0.54) POLBBRD4CREBBPJAK3KDM4E
SCHEMBL3646066 0.75 BRD4 (0.45) POLBBRD4CREBBPJAK3KDM4E
SCHEMBL23406001 0.74 BRD4 (0.44) POLBBRD4CREBBPJAK3KDM4E
SCHEMBL29743981 0.74 BRD4 (0.44) POLBBRD4CREBBPJAK3KDM4E
SCHEMBL7455067 0.73 SLC6A3 (0.42) BRD4KDM4ETSHRSLC6A3ABCB11
SCHEMBL29743964 0.72 TRPM8 (0.48) POLBBRD4CREBBPKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-10 US disclosed
EP-3760633-B1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2021-12-15 EP disclosed
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2021-02-11 US disclosed
EP-3760633-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof WNK1, WNK2, WNK3 POLB 2228/4885BRD4 2379/4885CREBBP 2432/4885
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF WNK1, WNK2, WNK3 POLB 2228/4885BRD4 2379/4885CREBBP 2432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.